Selina M. Luger, MD
Hematology
Headshot of Selina M. Luger, MD

Selina M. Luger, MD

she/her/hers
Hematology
Accepting new patients
Sees patients age 18 and up
Abramson Cancer Center Perelman 4th Floor West
Headshot of Selina M. Luger, MD
Penn Medicine Provider

About me

  • Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania

My education and training

  • McGill UniversityMedical School
  • Penn Presbyterian Medical CenterResidency
  • University of Pennsylvania Health SystemFellowship

Spoken languages

English
English
Français
French

Reviews

Average Rating

563 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

Anonymous
October 2026
Dr. Luger is an expert in MDS. I would recommend her to any room with MDS.
Anonymous
September 2026
Very knowledgeable
Anonymous
September 2026
Knowledge and experience
Anonymous
September 2026
I believe she is top in her field.

Insurance accepted

Please contact the practice and/or the member services department of your insurance company for specific details before receiving services. Providers may participate in some, but not all, products offered by a health plan; providers may also accept plans at some practice locations but not others.

Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
Dr. Luger is a Penn Medicine physician.

Qualifications and experience

All conditions and treatments

Research

Publications

Ferthio R, Bruno XJ, Garfall AL, Cohen AD, Kapur S, Lai CE, Luger SM, Stadtmauer EA, Vogl DT, Waxman A, Susanibar-Adaniya SP. Teclistamab in multiple myeloma with coexisting myelodysplastic syndrome or acute myeloid leukemia , Haematologica: 2026


Zugmaier G, Goekbuget N, Luger S, Litzow M, Cario G, Locatelli F. Depletion of CD19-positive B-cells and dexamethasone premedication may result in immune suppression in patients with B-precursor acute lymphoblastic leukemia after consolidation treatment with blinatumomab , Haematologica: 2026


Zhong X, Roberts KG, Wei H, Sun Z, Montefiori LE, Kumar A, Iacobucci I, Baviskar P, Gao Q, Pölönen P, Pruett-Miller SM, Schreiber RM, Chang TC, Zhang W, Lei S, Rampersaud E, Fan Y, Wu G, Mattison RJ, Zhang Y, Racevskis J, Lazarus HM, Rowe JM, Arber DA, Wieduwilt MJ, Abou Mourad Y, Shami PJ, Baer MR, Asch AS, O'Dwyer KM, Hall A, Liedtke M, Bergeron J, Wood BL, Pratz KW, Dinner SN, Frey NV, Gore SD, Bhatnagar B, Atallah EL, Uy GL, Jeyakumar D, Lin TL, Willman CL, Podoltsev NA, DeAngelo DJ, Patel S, Elliott MA, Advani AS, Tzachanis D, Vachhani P, Bhave RR, Sharon E, Little RF, Erba HP, Stone RM, Tallman MS, Yang JJ, Luger SM, Paietta E, Litzow MR, Mullighan CG. Genomic drivers of leukemia and blinatumomab response in adult acute lymphoblastic leukemia - the ECOG-ACRIN E1910 study , Blood: 2026


Tremblay D, Chen L, Sun Z, Ganzel C, Fernandez H, Foran J, Arber DA, Lazarus H, Zhang Y, Paietta E, Bennett JM, Rowe J, Litzow M, Tallman M, Atallah E, Luger S. Bone marrow biopsy characteristics at nadir after intensive induction therapy do not predict outcomes in adult acute myeloid leukemia patients: an analysis of ECOG-ACRIN clinical trials , Haematologica: 2026


Silva WF, Yin J, Liedtke M, Claxton DF, Fulton N, Giri S, Malnassy G, Mrózek K, Paietta E, Mullighan CG, Galinsky I, Bogart JA, Grecula JC, Kennedy L, Larson RA, Stone RM, Uy GL, Luger SM, Advani AS, Stock W. Long-term follow-up of a pediatric regimen for AYA with Ph-negative ALL: 10-year survival of CALGB 10403 (alliance) , Blood Adv, 10: 2026,5487-5491


Kharfan-Dabaja MA, Kumar A, Pemmaraju N, Murthy H, Al Malki M, Bashir Q, Bubis J, Lane AA, Nishihori T, de Lima M, Gangat N, Jamy O, Konopleva M, Luger S, Savani B, Sweet K, Wang E, Carpenter PA, Hamadani M. Hematopoietic Cell Transplantation for Blastic Plasmacytoid Dendritic Cell Neoplasm: Clinical Practice Guidelines From the American Society for Transplantation and Cellular Therapy , Transplant Cell Ther: 2026


Boulter AC, Li Y, Wang X, Zheng DJ, Pratz K, Luger S, Aplenc R, Getz KD. Primary Cardioprotection in Frontline Anthracycline Therapy for Adult Hematologic Cancers , JAMA Netw Open, 9: 2026,e2630536


Montesinos P, Altman JK, Bullinger L, Cheong JW, Fathi AT, Levis MJ, Luger S, Miyamoto T, Oliva EN, Perl AE, Récher C, Veiga RR, Wang J, Zeidan AM, Liu L, Duong Y, Rohrbach JEC, Inghirami G, Alexis K, Gosberg A, Nahar A, Burns K, Daver N, Erba HP. QuANTUM-Wild: a Phase III, randomized trial of quizartinib in newly diagnosed FLT3-ITD-negative acute myeloid leukemia. Future Oncol. 2026 Jul;22(16):1913-1924. doi: 10.1080/14796694.2026.2689464. Epub 2026 Jul 11. PMID: 42434847; PMCID: PMC13390524. QuANTUM-Wild: a Phase III, randomized trial of quizartinib in newly diagnosed FLT3-ITD-negative acute myeloid leukemia , Future Oncology, 22: 2026


Lee J, Sun R, Kume K, Robinson ME, Cheng Z, Cosgun KN, Ma N, Hurtz C, Geng H, Luger SM, Litzow MR, Paietta E, Chen J, Vaidehi N, Müschen M. Dynamic feedback control of oncogenic tyrosine kinase signaling in acute leukemia , Sci Signal, 19: 2026,eadw5054


Anderson DR, Gangaraju R, Sedhom WG, Hamulyák EN, Wang TF, O'Dwyer K, Carney BJ, Muthiah C, Liedtke M, Badar T, Shimony S, Robinson R, Sanfilippo K, Derkach A, Dinner S, Biemond BJ, Nemirovsky D, Goldberg LA, Kapadia AD, Levavi H, Bar-Natan M, Van Hyfte G, Bansal K, Carrier M, Fulcher J, Gerrits AM, Litzow MR, Luger S, Guru Murthy GS, Luskin M, Wolach O, Shomali W, Zwicker JI, Stock W, Leader A. Derivation and external validation of a venous thromboembolism risk prediction model in asparaginase-treated ALL , Blood Adv, 10: 2026,593-603